Trulieve Receives DEA Registrations for State-Licensed Medical Marijuana Operations
TALLAHASSEE, Fla., Nov. 2, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., today announced that Trulieve has received registrations for medical marijuana dispensaries as part of the initial registrations issued by the U.S. Drug Enforcement Administration (DEA). On Friday, the DEA announced it has begun the initial issuance of federal registrations to qualifying state licensed medical marijuana dispensaries, marking the first phase of the Attorney General's order in April that established a federal framework for qualifying medical marijuana businesses while maintaining federal controls under the Controlled Substances Act. In April, Trulieve applied for DEA registration for its state-licensed operations following the rescheduling of state-licensed medical marijuana to Schedule III under the Controlled Substances Act.
"Today marks another historic milestone for patients, physicians, and Trulieve, made possible by the bold action taken by the Trump Administration on common sense cannabis reform," said Trulieve Chief Executive Officer Kim Rivers. "Federal reclassification of state licensed medical marijuana opens the door for clinical research while creating a level playing field for responsible operators like Trulieve. We appreciate the DEA's work to advance this historic change and its continued engagement with state-licensed medical cannabis operators as the new federal framework is implemented."
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the NYSE under the symbol TRLV. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve
X: @Trulieve
Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-receives-dea-registrations-for-state-licensed-medical-marijuana-operations-302926512.html
This press release may not be republished, redistributed, resold or sublicensed without the prior written approval of PR Newswire.
AlphAI analysis
Written by AlphAI from the release above, not by the issuer or PR Newswire. Informational, not investment advice.
The 30-second read
Why it matters
The approval enables Trulieve to operate under federal oversight, potentially unlocking research opportunities and broader market participation.
Market read
First‑time DEA registration for a U.S. cannabis operator; likely catalyst for TRLV and sector sentiment.
What to watch
Potential compliance costs and state‑level regulatory hurdles could temper upside.
Background
Trulieve is a leading multi‑state medical cannabis operator listed on the NYSE (TRLV). The DEA's new registration framework follows the April rescheduling of medical cannabis to Schedule III.
Ticker impact
Trulieve received its first DEA registrations for state‑licensed medical marijuana dispensaries, a new regulatory approval disclosed for the first time.
upward pressure as investors price in expanded operational capability and potential growth
Regulatory clearance is a material catalyst for a cannabis operator; the market typically reacts positively to such approvals.
Market effects
May boost sentiment for the broader U.S. medical cannabis sector as the first DEA registrations set a precedent.
Strengthens the Florida and multi‑state cannabis market outlook.
Limited to U.S. cannabis operators; no immediate global impact.
Counterpoint
If DEA oversight tightens later, the benefit could be short‑lived; investors may wait for further regulatory clarity.
Key entities
- companyTrulieve Cannabis Corp.
NYSE‑listed medical cannabis operator receiving DEA registrations.
- regulatory_bodyDEA
U.S. Drug Enforcement Administration issuing the registrations.